Pro-Dex Q1 EPS Boosted by Ascendiant Capital Markets

Key Points

• Ascendiant Capital Markets raised its earnings outlook for Pro-Dex, increasing Q1 2027 EPS to $0.67 from $0.66 and projecting $3.09 EPS for FY2027 and $3.36 for FY2028. The firm maintained a Buy rating and $74 price target.
• Pro-Dex recently exceeded quarterly expectations, reporting $0.87 EPS versus the $0.67 consensus and revenue of $20.40 million versus $19.20 million expected. The company posted a 17.62% net margin and 25.13% return on equity.
• Analyst sentiment is broadly positive, with the stock carrying a Moderate Buy consensus rating and a $74 average target price, although insiders—including the CFO and CEO—sold shares recently under disclosed transactions.

Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) - Equities researchers at Ascendiant Capital Markets upped their Q1 2027 earnings estimates for Pro-Dex in a report issued on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now forecasts that the medical instruments supplier will post earnings per share of $0.67 for the quarter, up from their prior forecast of $0.66. Ascendiant Capital Markets currently has a "Buy" rating and a $74.00 price target on the stock. The consensus estimate for Pro-Dex's current full-year earnings is $2.78 per share. Ascendiant Capital Markets also issued estimates for Pro-Dex's Q2 2027 earnings at $0.72 EPS, Q3 2027 earnings at $0.82 EPS, FY2027 earnings at $3.09 EPS, Q1 2028 earnings at $0.77 EPS, Q2 2028 earnings at $0.81 EPS, Q3 2028 earnings at $0.86 EPS, Q4 2028 earnings at $0.91 EPS and FY2028 earnings at $3.36 EPS.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last released its earnings results on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.20. The firm had revenue of $20.40 million during the quarter, compared to the consensus estimate of $19.20 million. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%.

Several other research analysts have also issued reports on the stock. Zacks Research upgraded shares of Pro-Dex to a "hold" rating in a research report on Tuesday, May 19th. Wall Street Zen upgraded Pro-Dex from a "hold" rating to a "buy" rating in a report on Saturday, June 13th. Finally, Weiss Ratings raised shares of Pro-Dex from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, September 4th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $74.00.

Pro-Dex Trading Up 0.5%

Shares of PDEX stock opened at $66.91 on Wednesday. Pro-Dex has a fifty-two week low of $23.47 and a fifty-two week high of $77.00. The company has a quick ratio of 2.45, a current ratio of 4.10 and a debt-to-equity ratio of 0.28. The stock has a 50-day simple moving average of $62.68 and a 200 day simple moving average of $58.18. The stock has a market capitalization of $214.31 million, a P/E ratio of 16.20 and a beta of 0.06.

Insider Activity at Pro-Dex

In other news, CFO Alisha Charlton sold 2,300 shares of the firm's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total transaction of $140,990.00. Following the completion of the transaction, the chief financial officer directly owned 21,870 shares of the company's stock, valued at approximately $1,340,631. This trade represents a 9.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kirk Richard Lee Van, Jr. sold 765 shares of Pro-Dex stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $59.36, for a total value of $45,410.40. Following the sale, the chief executive officer directly owned 79,228 shares in the company, valued at $4,702,974.08. The trade was a 0.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 22,300 shares of company stock valued at $1,351,657 over the last three months. 45.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Morgan Dempsey Capital Management LLC raised its holdings in shares of Pro-Dex by 6.2% in the first quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier's stock valued at $286,000 after buying an additional 339 shares during the last quarter. Punch & Associates Investment Management Inc. boosted its stake in Pro-Dex by 2.9% in the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier's stock valued at $3,032,000 after acquiring an additional 1,735 shares during the last quarter. Navellier & Associates Inc. acquired a new stake in shares of Pro-Dex during the second quarter worth $322,000. Corsair Capital Management L.P. acquired a new position in shares of Pro-Dex during the 1st quarter worth about $532,000. Finally, Bank of New York Mellon Corp acquired a new position in Pro-Dex during the second quarter valued at approximately $678,000. 15.28% of the stock is owned by institutional investors.

Pro-Dex News Roundup

Here are the key news stories impacting Pro-Dex this week:

• Positive Sentiment: Ascendiant raises long-term earnings forecasts: Ascendiant Capital Markets lifted its FY2027 EPS estimate to $3.09 from $2.78 and maintained a “Buy” rating with a $74 price target. The firm projects EPS of $3.36 for FY2028, with quarterly estimates ranging from $0.77 to $0.91. The higher forecasts suggest expectations for continued profit growth at the medical-instruments supplier. Ascendiant Capital Markets analyst coverage
• Positive Sentiment: Several near-term estimates were increased: Ascendiant raised its Q1 2027 EPS forecast to $0.67 from $0.66, Q2 2027 to $0.72 from $0.69, and Q3 2027 to $0.82 from $0.74. These upward revisions provide a potential catalyst for the stock by indicating improving expectations for upcoming results.
• Positive Sentiment: Recent results exceeded expectations: Pro-Dex’s latest quarterly report showed $0.87 in EPS versus the $0.67 consensus estimate and revenue of $20.40 million versus estimates of $19.20 million. The company also reported a 17.62% net margin and 25.13% return on equity, reinforcing the bullish earnings narrative.
• Positive Sentiment: Institutional interest increased: Several funds initiated or expanded positions, including Bank of New York Mellon, Corsair Capital Management, Navellier & Associates, and California State Teachers’ Retirement System. Institutional investors collectively own approximately 15.28% of PDEX shares.
• Negative Sentiment: CEO disclosed a stock sale: CEO Kirk Richard Lee Van, Jr. sold 765 shares for approximately $45,410 under a pre-arranged Rule 10b5-1 trading plan. The sale reduced his holdings by less than 1%, limiting its significance, but insider selling can be a modest sentiment headwind. Pro-Dex CEO stock sale

About Pro-Dex

Pro-Dex, Inc is a medical device manufacturer that designs, develops and produces powered surgical instruments and related equipment. The company primarily serves original equipment manufacturers (OEMs), which incorporate Pro-Dex products into surgical systems sold under their own brands.

Its product portfolio includes battery-powered and electric handpieces, controllers, drivers, saws, microdebriders and other precision instruments used in medical and dental procedures. Pro-Dex also provides related components and accessories, including batteries, chargers and instrument controls, as well as engineering, manufacturing and product-development support for its customers.

Based in Irvine, California, Pro-Dex serves customers in the United States and international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.